Profile

Jill Ohar, M.D.Wake Forest School of Medicine

Doctor Rating

No Rating Available
Why No Ratings?

Jill Ohar, M.D.

Professor,

Clinical Interests

General Pulmonary Diseases, Lung Cancer, Chronic Obstructive Pulmonary Disease (COPD), Occupational Lung Disease

Contact Information

Department: 336-716-2011

Insurance Accepted »

Education & Training

  • B.S., Muhlenberg College, 1973
  • M.D., Med Coll Of Pennsylvania, 1977
  • Internship, Medicine, V.A. Hospital, 1979
  • Internship, Medicine, Med Coll Virginia Hosps, 1981
  • Fellowship, Medicine, Medical College of Va., VCU, 1985

Board Certifications

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Pulmonary Disease

Memberships

  • Nat'L Board Of Medical Examine
  • Amer Coll Of Chest Physicians
  • Am Coll Of Physicians
  • American Thoracic Society

NPI Number

  • 1376526400
Jill Ohar, M.D.

Doctor Rating

No Rating Available
Why No Ratings?

Jill Ohar, M.D.

Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine

Research Interests

Pulmonary Disease, Chronic Obstructive; Bronchodilator Agents; Smoking; Asbestos; Glucocorticoids
More »

Contact Information

Academic: 336-716-4843 | Department: 336-716-2011

Recent Publications

Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR.. Cancer Res. 2016;76(2):206-215.

Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Kumbhare S, Pleasants R, Ohar JA, Strange C.. Ann Am Thorac Soc. 2016;13(6):803-810.

Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C.. J Asthma. 2016;53(7):720-731.

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Cohen JS, Miles MC, Donohue JF, Ohar JA.. Int J Chron Obstruct Pulmon Dis. 2016;11():785-797.

A retrospective study of two populations to test a simple rule for spirometry. Ohar JA, Yawn BP, Ruppel GL, Donohue JF.. BMC Fam Pract. 2016;17(1):65.

Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines. Davidson JF, Donohue JF, Ohar JA.. Expert Opin Drug Saf. 2015;14(2):317-324.

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Loh CH, Donohue JF, Ohar JA.. Expert Opin Drug Saf. 2015;14(3):463-472.

Changing pattern in malignant mesothelioma survival. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA.. Transl Oncol. 2015;8(1):35-39.

Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Liu Y, Pleasants RA, Croft JB, Lugogo N, Ohar J, Heidari K, Strange C, Wheaton AG, Mannino DM, Kraft M.. Respir Med. 2015;109(7):851-859.

Smoking duration, respiratory symptoms, and COPD in adults aged greater than or equal to 45 years with a smoking history. Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C.. Int J Chron Obstruct Pulmon Dis. 2015;10():1409-1416.

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR.. Cancer Lett. 2015;369(2):261-265.

Risks may not be reasons for COPD readmissions [editorial]. Ohar JA.. Ann Am Thorac Soc. 2015;12(9):1259-1260.

Targeting persons with or at high risk for chronic obstructive pulmonary disease by state-based surveillance. Pleasants RA, Heidari K, Wheaton AG, Ohar JA, Strange C, Croft JB, Liao W, Mannino DM, Kraft M.. COPD. 2015;12(6):680-689.

Prevalence of BAP1 germline mutations in asbestos-exposed malignant mesothelioma cases and controls [abstract]. Cheung M, Talarchek J, Howard SE, Howard T, Peng HZ, Hesdorffer M, Rauscher FJ, Ohar JA, Testa J.. Cancer Res. 2015;75(15 Suppl):2752.

Poor perception of symptoms and functional limitation affects COPD diagnosis [abstract]. Loh C, Donohue JF, Morgan TM, Collins J, Ohar JA.. Am J Respir Crit Care Med. 2015;191():A4481.

Sex-based differences in asthma-chronic obstructive pulmonary disease overlap syndrome in respiratory symptoms, health impairment, and comorbidities [abstract]. Pleasants RA, Wheaton AG, Croft JB, Liu Y, Heidari K, Ohar JA, Kraft M, Lugogo N, Mannino DM, Strange CB.. Am J Respir Crit Care Med. 2015;191():A4452.

Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL.. COPD. 2014;11(3):256-266.

Fluticasone propionate/salmeterol 250/50 mcg versus salmeterol 50 mcg after chronic obstructive pulmonary disease exacerbation. Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT.. Respir Res. 2014;15():105.

Nebulized arformoterol: what is its place in the management of COPD?. Miles MC, Donohue JF, Ohar JA.. Ther Adv Respir Dis. 2013;7(2):81-86.

Effects of fluticasone propionate/salmeterol combination 250/50mcg BID (ADVAIR DISKUS) vs. salmeterol 50mcg BID (SEREVENT DISKUS). Ohar JA, Crater G, Emmett A, Ferro T, Morris A, Raphiou I, Sriram P, Dransfield MT.. Am J Respir Crit Care Med. 2013;187():A2439.

Comparison of different behavioral risk factor surveillance system methods on COPD epidemiological measures [abstract]. Pleasants R, Ohar JA.. Am J Respir Crit Care Med. 2013;187():A3167.

COPD appears to lead to increased costs and enhance morbidity [abstract]. Ohar JA, Edwards A, Howard S, Benshoff M, Donohue JF.. Am J Respir Crit Care Med. 2013;187():A5510.

Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?. Miles MC, Donohue JF, Ohar JA.. Drugs. 2012;72(3):301-308.

Prevalence and impact of unrecognized COPD on elective surgery [abstract]. Ohar J, Edwards A, Howard S, Benshoff M, Donohue J.. Eur Respir J. 2012;40(Suppl 56):620s-621s.

Restricted spirometry pattern in long term smokers--characteristics and association with heart disease [abstract]. Ohar JA, Ruppel GL, Make BJ, Donohue JF.. Am J Respir Crit Care Med. 2012;185():A6043.

Combination therapy for COPD: emerging evidence from recent clinical trials. Miles MC, Donohue JF, Ohar JA.. Clin Investig (Lond). 2011;1(6):879-890.

Reconsidering sex-based stereotypes of COPD. Ohar J, Fromer L, Donohue JF.. Prim Care Respir J. 2011;20(4):370-378.

Do symptoms predict COPD in smokers?. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER.. Chest. 2010;137(6):1345-1353.

COPD is associated with a macrophage scavenger receptor-1 gene sequence variation. Ohar JA, Hamilton RF Jr, Zheng S, Sadeghnejad A, Sterling DA, Xu J, Meyers DA, Bleecker ER, Holian A.. Chest. 2010;137(5):1098-1107.

Replication of an association of the interleukin-1 receptor antagonist gene with asthma in an adult urban admixed population [abstract]. Sadeghnejad A, Ohar JA, Bleecker ER, Meyers D.. Am J Respir Crit Care Med. 2010;181(1 Meeting Abstracts):A3877.

Genome wide association study in mesothelioma [abstract]. Ohar JA, Howard TD, Ampleford EJ, Bleecker ER, Meyers DA.. Am J Respir Crit Care Med. 2010;181(1 Meeting Abstracts):A4340.

Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Ohar JA, Donohue JF.. Semin Respir Crit Care Med. 2010;31(3):321-333.

Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER.. Respir Res. 2009;10():article 21.

Role of SERPINE2 in asthma and COPD [abstract]. Sadeghnejad A, Koppelman GH, Ohar JA, Postma DS, Bleecker ER, Meyers DA.. Am J Respir Crit Care Med. 2009;179(Online Abstr Issue):A2741.

Symptoms poorly predict the presence of COPD in at-risk smokers [abstract]. Ohar JA, Sadeghnejad A, Meyers DA, Bleecker ER.. Am J Respir Crit Care Med. 2009;179(Online Abstr Issue):A1471.

An official American Thoracic Society policy statement: managing conflict of interest in professional societies. Schunemann HJ, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, Ohar J, McDermott S, Lucas L, Jaeschke R.. Am J Respir Crit Care Med. 2009;180(6):564-580.

It's about time--directing our attention toward modifying the course of COPD. Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S.. J Respir Med. 2008;102(Suppl 1):S37-S48.

Polymorphisms in MSR1 gene affect macrophage function [abstract]. Ohar JA, Holian A, Sadeghnejad A, Hamilton RF, Zheng SL, Xu J, Meyers DA, Bleecker ER.. Am J Respir Crit Care Med. 2008;177(Online Abstr Issue):A503.

ADAM33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers [abstract]. Sadeghnejad A, Ohar JA, Zheng SL, Hawkins GA, Meyers DA, Bleecker ER.. Am J Respir Crit Care Med. 2008;177(Online Abstr Issue):A504.

Identification of a mesothelioma phenotype. Ohar JA, Ampleford EJ, Howard SE, Sterling DA.. Respir Med. 2007;101(3):503-509.

IL13 promoter polymorphism enhances the adverse effect of smoking on lung function [abstract]. Sadeghnejad A, Meyers DA, Bleeker [sic] ER [Bleecker ER], Ohar JA.. Am J Respir Crit Care Med. 2007;175(Abstr Issue):A563.

IL13 promoter polymorphism -1112C/T modulates the adverse effect of tobacco smoking on lung function. Sadeghnejad A, Meyers DA, Bottai M, Sterling DA, Bleecker ER, Ohar JA.. Am J Respir Crit Care Med. 2007;176(8):748-752.

Mesothelioma: you do not have to work for it. Ampleford EJ, Ohar J.. Diagn Cytopathol. 2007;35(12):774-777.

Smoking trends have led to increased mortality: COPD in women, part 1: a review of recent trends. Ohar J, McCallister J.. J Respir Dis. 2006;27(2):70-74.

Should sex differences affect the approach to treatment? COPD in women, part 2: treatment considerations. Ohar J, McCallister J.. J Respir Dis. 2006;27(3):115-122.

ADAM33 is associated with COPD in a large US population [abstract]. Ohar JA, Ampleford EJ, Sterling DA, Bleecker ER, Meyers DA.. In: American Thoracic Society International Conference Abstracts; 2006 May 19-24; San Diego (CA). 2006;():A620.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine

Clinical Interests

General Pulmonary Diseases, Lung Cancer, Chronic Obstructive Pulmonary Disease (COPD), Occupational Lung Disease

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.